Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953820 · ClinicalTrials.gov registry record · Phase 1
Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study
A Phase 1 study of Epilepsy, sponsored by Aquestive Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 3
- Study locations
NCT03953820 is a Phase 1 study of Epilepsy that has completed, run by Aquestive Therapeutics. The registered enrollment target is 31 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03953820, a Phase 1 study of Epilepsy, has completed, sponsored by Aquestive Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 3
- Study locations
Study Summary
This was a multiple centers, single-dose, open-label, randomized two-sequence crossover, two-period study to evaluate the pharmacokinetics (PK) of single doses of Diazepam Buccal Film (DBF) compared with Diastat® Rectal Gel (DRG) under fed conditions in adult male and female participants on a stable concomitant regimen of anti-epileptic drugs for the treatment of epilepsy.
Conditions Studied
Interventions
- DRUG Diazepam Buccal Film
- DRUG Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Study Locations (3)
Florida
- Clinical Trials of Florida, LLC - Miami
- Bioclinica Research - Orlando
- Florida Premier Research Institute, LLC - Winter Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-04-13 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953820
The ClinicalTrials.gov registry entry for NCT03953820 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is Aquestive Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Diazepam Buccal Film is the first listed.
NCT03953820 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03953820 about?
NCT03953820 is a clinical study titled "Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study". This was a multiple centers, single-dose, open-label, randomized two-sequence crossover, two-period study to evaluate the pharmacokinetics (PK) of single doses of Diazepam Buccal Film (DBF) compared with Diastat® Rectal Gel (DRG) under fed conditions in adult male and female participants on a stable...
What is the current status of trial NCT03953820?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2019-04-13. Estimated completion is 2019-07-31.
What conditions does trial NCT03953820 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT03953820?
The interventions under investigation include: Diazepam Buccal Film (DRUG), Diastat® Rectal Gel (Valeant Pharmaceuticals USA) (DRUG).
Who is sponsoring clinical trial NCT03953820?
This trial is sponsored by Aquestive Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03953820 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Ketamine's Dissociative Effects (KD Study)
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.